Mutant IDH1-IN-2
Mutant IDH1-IN-2 is a inhibitor of mutant Isocitrate dehydrogenase (IDH) proteins, with IC50 of in LS-MS biochemical assay, IC50 of 16.6 nM in Fluorescence biochemical assay. Target: Mutant IDH1 Mutant IDH1-IN-2 has a neomorphic activity and in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer. More bioactivity information in Patent WO 2013046136A1 (Example 224) .
Product Specifications
CAS Number
[1429176-69-1]
UNSPSC
12352005
Target
Isocitrate Dehydrogenase (IDH)
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Mutant-IDH1-IN-2.html
Purity
98.50
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C1OC[C@H](C(C)C)N1C2=NC(N[C@H](C3=CC=C(CN4CCC(F)(F)CC4)C=C3)C)=NC=C2
Molecular Formula
C24H31F2N5O2
Molecular Weight
459.53
References & Citations
[1]Huangshu, et al. 3-Pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH and their preparation
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
IDH1
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
AGAP9, NT (AGAP9, CTGLF6, Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 9, Centaurin-gamma-like family member 6) (MaxLight 490) discontinued
